Press release

DSM reports strong 2010 results and proposes dividend increase to €1.35

Heerlen, NL, 23 Feb 2011 07:15 CET

  • Vision 2010 strategy successfully completed; DSM will now drive focused growth
  • Q4 operating profit from continuing operations up 17% to €170 million
  • Full-year operating profit from continuing operations up 74% to €752 million
  • Very good Nutrition performance drives Life Sciences results
  • Significant improvement in Materials Sciences results
  • Continued strong cash flow from operating activities of €1.1 billion in 2010
  • Dividend increase of 12.5% to €1.35 per ordinary share proposed for 2010
  • 2011 is expected to be another strong year for DSM towards achieving the 2013 targets

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “I am proud to report such strong financial results for 2010, which reflect our focus on innovation and our customers across the globe as well as cost and cash management supported by an improving economic climate. Within the Life Sciences businesses, our Nutrition business continued to record very good results, whilst Pharma needs improvement. The Materials Sciences businesses delivered a significant improvement during the year with a record result for Polymer Intermediates.

The year 2010 was the last in a period of transformation for DSM to become a focused Life Sciences and Materials Sciences company. We successfully completed our Vision 2010 strategy, including divesting the remaining non-core assets within the promised timescale. Subsequently, through a series of important transactions we have started to build additional strong growth platforms for the next phase of our strategy ‘DSM in motion: driving focused growth’ as evidenced by the announced acquisition of Martek and the announced joint venture with Sinochem for our anti-infectives business. We are confident that 2010 has laid the foundation for achieving our new strategic growth and profitability objectives and therefore we are proposing to raise our dividend from €1.20 to €1.35 instead of the €1.30 announced in September 2010.”

Key figures

Q4 2010Q4 2009+/-in € millionFY 2010FY 2009+/-
   Continuing operations:   
2,0821,75818%Net sales8,1766,72522%
2762606%Operating profit before depreciation & amortization (EBITDA)1,16183439%
17014517%Operating profit (EBIT)75243374%
136137 Nutrition569521 
1216 Pharma732 
3023 Performance Materials17968 
5511 Polymer Intermediates1926 
-63-42 Other activities-195-194 
   Discontinued operations:   
120258 Net sales8741,141 
1415 Operating profit before depreciation & amortization (EBITDA)11783 
10-3 Operating profit (EBIT)8610 
   Total DSM:   
2,2022,0169%Net sales9,0507,86615%
18014227%Operating profit (EBIT)83844389%
11789 Net profit before exceptional items547244 
32-149 Net result from exceptional items-4093 
149-60 Net profit507337 
   Net earnings per ordinary share in €:   
0.630.54 before exceptional items, continuing operations2.891.44 
0.89-0.39 including exceptional items, total DSM3.032.01 

You can find the press release in full, including financial statements, below.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420

Dave Huizing

Vice President Investor Relations
+31 45 578 2864

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864